HTG Molecular Diagnostics Completes Initial Technical Feasibility Testing with QIAGEN GeneReader NGS System

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology has been successfully adapted for use with the QIAGEN GeneReader NGS System based on the results of initial technical feasibility tests. Results from samples tested with the HTG EdgeSeq DLBCL Cell of Origin Assay gene panel adapted for detection with the GeneReader NGS System showed strong correlation (r = 0.98) to data previously generated on the MiSeq sequencer.

“We are pleased to show the feasibility of using our HTG EdgeSeq technology with the GeneReader NGS System, which will expand the sequencing platforms available for use with our system, and, importantly, advances our precision diagnostics collaboration with QIAGEN. The HTG and QIAGEN teams have been working very closely and we are delighted with their speed and efficiency to accomplish this initial feasibility milestone,” stated TJ Johnson, Chief Executive Officer of HTG.

“Adapting our HTG EdgeSeq technology for detection on the GeneReader NGS System has been fairly straightforward to date and the initial testing results were gratifying,” said Debrah Thompson, Ph.D., HTG’s Vice President of Research. “The level of cooperation between the QIAGEN and HTG technical teams has been outstanding, and we are excited about the future of this collaboration.”

About HTG:

Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013, the company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG's original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the company’s HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.

Safe Harbor Statement:

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the results of initial feasibility testing using the GeneReader platform and our agreement and collaboration with QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN, N.V. (“QIAGEN”) and their expected benefits to us, and our business and the capabilities of our technology. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with our ability to successfully develop, market and/or commercialize new methods, technologies and/or products, including our ability to further adapt our technology to the GeneReader NGS System and expand the sequencing platforms available for use with our HTG EdgeSeq system, or successfully develop and commercialize any related products or services. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Annual Report on Form 10-K for the year ended December 31, 2016. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact:
Westwicke Partners
Jamar Ismail
Phone: [phone]
Email: [e-mail]

TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: [phone] x130
Email: [e-mail]